A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer
- Abstract
- PURPOSE: The aim of this study is to investigate the efficacy and safety of gemcitabine and oxaliplatin combination chemotherapy as first-line therapy in patients with inoperable biliary tract cancer (BTC). METHODS: The treatment of this non-randomized phase II study consisted of gemcitabine 1,000 mg/m(2) intravenously (i.v.) on day 1 and oxaliplatin 85 mg/m(2) i.v. on day 2 every 2 weeks until disease progression, unaccep toxicity or patients' refusal. RESULTS: From Sept 2006 to Oct 2007, 40 patients were enrolled. In the ITT analysis, the objective response rate was 15.0% and the disease control rate was 52.5%. The median overall survival (95% CI) was 8.5 months (6.4-10.7) and the time to progression was 4.2 months (0.5-7.9). For the 305 cycles, observed grade 3/4 toxicity was uncommon. CONCLUSIONS: Gemcitabine and dose adjusted oxaliplatin combination chemotherapy had moderate anti-tumor activity and was well tolerated as a first-line treatment for patients with inoperable BTC.
- All Author(s)
- H. J. Kim
; N. S. Lee
; S. C. Lee
; S. B. Bae
; C. K. Kim
; Y. G. Cheon
; Y. S. Kim
; J. H. Moon
; Y. D. Cho
; S. H. Park
; K. T. Lee
; S. K. Park
; J. H. Won
; H. S. Park
; D. S. Hong
- Issued Date
- 2009
- Type
- Article
- Keyword
- Biliary tract cancer; Gemcitabine; Oxaliplatin; Chemotherapy
- ISSN
- 0344-5704
- Citation Title
- Cancer Chemotherapy and Pharmacology
- Citation Volume
- 64
- Citation Number
- 2
- Citation Start Page
- 371
- Citation End Page
- 377
- Language(ISO)
- eng
- DOI
- 10.1007/s00280-008-0883-7
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/1706
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.